Structure–Activity Relationship Studies of Orally Active Antimalarial 3,5-Substituted 2-Aminopyridines
Journal of Medicinal Chemistry2012Vol. 55(24), pp. 11022–11030
Citations Over TimeTop 10% of 2012 papers
Diego González Cabrera, Frédèric Douelle, Yassir Younis, Tzu‐Shean Feng, Claire Le Manach, Aloysius T. Nchinda, Leslie J. Street, Christian Scheurer, Jolanda Kamber, Karen L. White, Oliver D. Montagnat, Eileen Ryan, Kasiram Katneni, K. Mohammed Zabiulla, Jayan T. Joseph, Sridevi Bashyam, David Waterson, Michael J. Witty, Susan A. Charman, Sergio Wittlin, Kelly Chibale
Abstract
In an effort to address potential cardiotoxicity liabilities identified with earlier frontrunner compounds, a number of new 3,5-diaryl-2-aminopyridine derivatives were synthesized. Several compounds exhibited potent antiplasmodial activity against both the multidrug resistant (K1) and sensitive (NF54) strains in the low nanomolar range. Some compounds displayed a significant reduction in potency in the hERG channel inhibition assay compared to previously reported frontrunner analogues. Several of these new analogues demonstrated promising in vivo efficacy in the Plasmodium berghei mouse model and will be further evaluated as potential clinical candidates. The SAR for in vitro antiplasmodial and hERG activity was delineated.
Related Papers
- → An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa(2015)39 cited
- → Is it time for Africa to adopt primaquine in the era of malaria control and elimination?(2022)7 cited
- → Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy(2016)19 cited
- → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)